Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older
- People with a confirmed diagnosis of invasive breast cancer, whether early-stage, advanced, or metastatic, at any point in their treatment journey
- People whose breast cancer tests negative for estrogen receptors (ER), progesterone receptors (PR), and HER2 protein (a type known as "triple-negative breast cancer")
- People with advanced or metastatic disease in the experimental group whose tumour tests positive for a protein called PD-L1 at specific levels (confirm with trial site)
- People in the experimental group for whom a treatment plan combining immunotherapy (ICI) and chemotherapy is being considered
- People who have provided written consent to participate in the ICK-breast registry
Who may not be able to join:
- People whose breast cancer tests positive for estrogen receptors (ER) or progesterone receptors (PR)
- People whose breast cancer tests positive for the HER2 protein at specific levels confirmed by laboratory testing
- Early-stage breast cancer patients who have already received any systemic (whole-body) breast cancer treatment before joining the trial
- People who have already received immunotherapy (ICI) treatment before joining the trial
- People who are currently pregnant or breastfeeding
- People whose overall health is not considered strong enough to tolerate chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tobias Engler, Dr., Department of Women's Health Tübingen
Phone: 07071 29 82211
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prognostic value of CRP kinetics under ICI therapy on pathologic complete response (PCR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.